Loading...
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4...
Saved in:
| Published in: | Card Fail Rev |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Radcliffe Cardiology
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970669/ https://ncbi.nlm.nih.gov/pubmed/33747548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/cfr.2020.19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|